Iratumumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Iratumumab is a monoclonal antibody designed for the treatment of various forms of cancer. This drug functions as an immune system modulator, targeting specific cells within the body to inhibit the growth and spread of malignant cells.
Mechanism of Action[edit | edit source]
Iratumumab works by binding to a specific antigen on the surface of cancer cells. This binding can lead to the direct inhibition of cancer cell growth, as well as the induction of an immune response against the targeted cells. The exact mechanism of action may vary depending on the type of cancer being treated.
Clinical Uses[edit | edit source]
Iratumumab is under investigation for its potential use in the treatment of multiple types of cancer, including leukemia, lymphoma, and solid tumors. Clinical trials are ongoing to determine its efficacy and safety in these different settings.
Pharmacokinetics[edit | edit source]
Details on the pharmacokinetics of Iratumumab, such as absorption, distribution, metabolism, and excretion, are currently being studied in clinical trials.
Adverse Effects[edit | edit source]
As with any cancer therapy, Iratumumab may cause side effects, which can vary widely among patients. Common adverse effects associated with monoclonal antibodies include infusion reactions, fatigue, and immune-related effects. Specific side effects related to Iratumumab will be better understood as clinical trial data becomes available.
Development and Regulatory Status[edit | edit source]
Iratumumab is still in the development phase and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The outcomes of ongoing clinical trials will determine its path towards approval and its future in cancer therapy.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
